BR112014030655A8 - Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende - Google Patents

Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende

Info

Publication number
BR112014030655A8
BR112014030655A8 BR112014030655A BR112014030655A BR112014030655A8 BR 112014030655 A8 BR112014030655 A8 BR 112014030655A8 BR 112014030655 A BR112014030655 A BR 112014030655A BR 112014030655 A BR112014030655 A BR 112014030655A BR 112014030655 A8 BR112014030655 A8 BR 112014030655A8
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
kinase inhibitors
pharmaceutical composition
composition including
pyrimidinyl
Prior art date
Application number
BR112014030655A
Other languages
English (en)
Other versions
BR112014030655A2 (pt
BR112014030655B1 (pt
Inventor
T Hopkins Brian
Conlon Patrick
R Chan Timothy
J Jenkins Tracy
Cai Xiongwei
Humora Michael
Shi Xianglin
A Miller Ross
Thompson Andrew
Original Assignee
Biogen Idec Inc
Biogen Ma Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Ma Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc
Priority to BR122021002178-3A priority Critical patent/BR122021002178B1/pt
Publication of BR112014030655A2 publication Critical patent/BR112014030655A2/pt
Publication of BR112014030655A8 publication Critical patent/BR112014030655A8/pt
Publication of BR112014030655B1 publication Critical patent/BR112014030655B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

COMPOSTOS INIBIDORES DE PIRIMIDINIL TIROSINA QUINASE, E COMPOSIÇÃO FARMACÊUTICA QUE OS COMPREENDE. A presente invenção fornece compostos e composições dos mesmos úteis como inibidores de tirosina quinase de Bruton e que apresentam características desejáveis para isso.
BR112014030655-9A 2012-06-08 2013-06-07 compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende BR112014030655B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021002178-3A BR122021002178B1 (pt) 2012-06-08 2013-06-07 Uso de compostos inibidores de pirimidinil tirosina quinase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
US61/657,360 2012-06-08
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
BR112014030655A2 BR112014030655A2 (pt) 2017-06-27
BR112014030655A8 true BR112014030655A8 (pt) 2018-01-02
BR112014030655B1 BR112014030655B1 (pt) 2021-04-20

Family

ID=49712704

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122021002178-3A BR122021002178B1 (pt) 2012-06-08 2013-06-07 Uso de compostos inibidores de pirimidinil tirosina quinase
BR112014030655-9A BR112014030655B1 (pt) 2012-06-08 2013-06-07 compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122021002178-3A BR122021002178B1 (pt) 2012-06-08 2013-06-07 Uso de compostos inibidores de pirimidinil tirosina quinase

Country Status (30)

Country Link
US (5) US9394277B2 (pt)
EP (3) EP3753934A1 (pt)
JP (6) JP6214643B2 (pt)
KR (4) KR102102587B1 (pt)
CN (3) CN113549055A (pt)
AR (1) AR091273A1 (pt)
AU (5) AU2013271407B2 (pt)
BR (2) BR122021002178B1 (pt)
CA (2) CA2875799C (pt)
CY (1) CY1120638T1 (pt)
DK (1) DK2858499T3 (pt)
EA (2) EA201790418A1 (pt)
ES (2) ES2834333T3 (pt)
HK (1) HK1209284A1 (pt)
HR (1) HRP20181294T1 (pt)
HU (1) HUE039897T2 (pt)
IL (2) IL235938B (pt)
IN (1) IN2014DN10576A (pt)
LT (1) LT2858499T (pt)
MX (2) MX363672B (pt)
NZ (1) NZ702715A (pt)
PH (2) PH12014502699B1 (pt)
PL (1) PL2858499T3 (pt)
PT (1) PT2858499T (pt)
RS (1) RS57978B1 (pt)
SG (2) SG11201408173WA (pt)
SI (1) SI2858499T1 (pt)
TW (3) TWI592406B (pt)
WO (1) WO2013185084A1 (pt)
ZA (1) ZA201409255B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN108947913A (zh) * 2013-12-11 2018-12-07 比奥根Ma公司 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
TN2018000218A1 (en) * 2014-10-24 2019-10-04 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors.
US11174243B2 (en) * 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
AU2001250849A1 (en) 2000-03-17 2001-10-03 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
PT1294724E (pt) 2000-06-26 2006-07-31 Pfizer Prod Inc Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7326712B2 (en) 2003-10-14 2008-02-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
US20080253960A1 (en) * 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
CA2586375A1 (en) * 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009521445A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
KR20090046872A (ko) 2006-07-26 2009-05-11 노파르티스 아게 운데카프레닐 피로포스페이트 합성효소의 억제제
JP2010502751A (ja) * 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
EP2201840B1 (en) * 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
MX2009009417A (es) * 2007-03-02 2009-09-11 Schering Corp Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
JP5291095B2 (ja) 2007-06-01 2013-09-18 グラクソスミスクライン エルエルシー イミダゾピリジンキナーゼ阻害剤
DK2242749T3 (da) 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
US8617823B2 (en) 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
EP2307025B1 (en) 2008-07-16 2017-09-20 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
CN102325753B (zh) * 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
EP3255047B1 (en) * 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
EP2435442B1 (de) 2009-05-25 2016-01-13 Sandoz AG Verfahren zur herstellung von ceftobiprol medocaril
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
US8685880B2 (en) * 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
CN108947913A (zh) 2013-12-11 2018-12-07 比奥根Ma公司 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance

Also Published As

Publication number Publication date
EP2858499A4 (en) 2016-01-20
DK2858499T3 (en) 2018-08-20
PH12014502699A1 (en) 2015-02-02
CN104540385A (zh) 2015-04-22
BR112014030655A2 (pt) 2017-06-27
CA3108186A1 (en) 2013-12-12
US20150158843A1 (en) 2015-06-11
LT2858499T (lt) 2018-09-10
CY1120638T1 (el) 2019-12-11
ES2834333T3 (es) 2021-06-17
IL277951A (en) 2020-11-30
TWI719209B (zh) 2021-02-21
EP3753934A1 (en) 2020-12-23
SG10201708535UA (en) 2017-11-29
MX363672B (es) 2019-03-29
CN113549055A (zh) 2021-10-26
TW201410668A (zh) 2014-03-16
HUE039897T2 (hu) 2019-02-28
AU2017201536A1 (en) 2017-03-23
EA027823B1 (ru) 2017-09-29
AU2019203476A1 (en) 2019-06-06
PH12018501463A1 (en) 2019-03-04
EP3385263A1 (en) 2018-10-10
CN109305959B (zh) 2022-02-08
US20230174511A1 (en) 2023-06-08
JP2021073298A (ja) 2021-05-13
JP2019077728A (ja) 2019-05-23
BR112014030655B1 (pt) 2021-04-20
KR20150036020A (ko) 2015-04-07
AU2013271407A1 (en) 2015-01-22
CN104540385B (zh) 2018-06-05
TWI792158B (zh) 2023-02-11
EP3385263B1 (en) 2020-07-22
SG11201408173WA (en) 2015-01-29
US10618887B2 (en) 2020-04-14
KR20220154850A (ko) 2022-11-22
US20190047986A1 (en) 2019-02-14
MX2014015044A (es) 2015-09-22
JP2023052415A (ja) 2023-04-11
AU2019203476B2 (en) 2021-01-28
EP2858499A1 (en) 2015-04-15
CA2875799A1 (en) 2013-12-12
CN109305959A (zh) 2019-02-05
KR20200043497A (ko) 2020-04-27
AU2021202412A1 (en) 2021-05-20
KR20210072139A (ko) 2021-06-16
AR091273A1 (es) 2015-01-21
AU2017201536B2 (en) 2019-03-07
AU2022275504A1 (en) 2023-01-05
TW201805279A (zh) 2018-02-16
BR122021002178B1 (pt) 2022-03-22
HRP20181294T1 (hr) 2018-10-05
US20210017155A1 (en) 2021-01-21
JP6214643B2 (ja) 2017-10-18
US9394277B2 (en) 2016-07-19
EA201492056A1 (ru) 2015-05-29
TWI592406B (zh) 2017-07-21
NZ702715A (en) 2016-11-25
HK1209284A1 (en) 2016-04-01
ES2684268T3 (es) 2018-10-02
IN2014DN10576A (pt) 2015-08-28
IL235938B (en) 2020-10-29
IL235938A0 (en) 2015-02-01
KR102468430B1 (ko) 2022-11-21
MX2019003618A (es) 2019-07-18
WO2013185084A1 (en) 2013-12-12
TW202142535A (zh) 2021-11-16
US9944622B2 (en) 2018-04-17
US20160304494A1 (en) 2016-10-20
EP2858499B1 (en) 2018-05-16
PL2858499T3 (pl) 2019-03-29
JP2017193583A (ja) 2017-10-26
CA2875799C (en) 2021-03-23
SI2858499T1 (sl) 2018-10-30
RS57978B1 (sr) 2019-01-31
AU2013271407B2 (en) 2016-12-08
JP2021073299A (ja) 2021-05-13
KR102102587B1 (ko) 2020-04-22
JP2015518903A (ja) 2015-07-06
EA201790418A1 (ru) 2017-11-30
PT2858499T (pt) 2018-10-24
ZA201409255B (en) 2015-12-23
PH12014502699B1 (en) 2015-02-02

Similar Documents

Publication Publication Date Title
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
BR112014017021A2 (pt) inibidores de irak e usos dos mesmos
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015028173A2 (pt) inibidores de acc e usos dos mesmos
BR112015028152A2 (pt) inibidores de acc e usos dos mesmos
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112015022861A8 (pt) inibidores de bromodomínio
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112015000561A2 (pt) inibidores de irak e usos dos mesmos
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
BR112015028171A8 (pt) Inibidores de acc e seu uso
BR112014013108A2 (pt) compostos tricíclicos fundidos como inibidores da quinase raf
BR112014028991A2 (pt) triazóis como inibidores de kv3
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112016009488A8 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica.
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil

Legal Events

Date Code Title Description
B25I Requirement for requested change of headquarter

Owner name: BIOGEN IDEC MA INC. (US) , SUNESIS PHARMACEUTICALS

B25D Requested change of name of applicant approved

Owner name: SUNESIS PHARMACEUTICALS, INC. (US) , BIOGEN MA INC

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25G Requested change of headquarter approved

Owner name: SUNESIS PHARMACEUTICALS, INC. (US) , BIOGEN MA INC

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2013, OBSERVADAS AS CONDICOES LEGAIS.